Royal Bank of Canada raised its price objective for Vertex Pharmaceuticals, with Benzinga and MarketBeat reporting related analyst changes.
3 reports, 1 independent
Updated Tue 00:00
Still developing
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Royal Bank of Canada raised its price objective for Vertex Pharmaceuticals, with Benzinga and MarketBeat reporting related analyst changes.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Vertex Pharmaceuticals
American pharmaceutical company
-
Royal Bank of Canada
financial institution in Canada
Related events
- Royal Bank of Canada issued a price objective and Benzinga reported a target price reduction for Aardvark Therapeutics, Inc.
- Financial institutions Morgan Stanley, Royal Bank of Canada, and Citigroup issued various rating and price target updates for Howmet Aerospace.
- MarketBeat is providing average rating data as Royal Bank of Canada issues a price target report regarding ConocoPhillips.
- RBC and Citigroup boosted price objectives on Lockheed Martin shares, with MarketBeat aggregating the analyst ratings.
- Financial firms, including Jefferies, RBC, and Wells Fargo, issued rating and price objective updates for Biogen.